Introduction

• For the past 20 years, management of hemoglobin (Hb) level via erythropoiesis-stimulating agents (ESAs), such as epoetin alfa (EPO) has been standard in the treatment of anemia in end-stage renal disease (ESRD) patients.1

• US dialysis centers typically dose ESAs at every session (three times per week), enabling frequent dose titrations. However, a once-monthly ESA has recently been approved by the US Food and Drug Administration for use in adult ESRD patients.1

• We have recently demonstrated that more frequent Hb measurements and ESA dose titrations by physicians are not associated with improved patient-time in target Hb range, but are associated with increased ESA use.2

• Frequent Hb measurements and dose titrations associated with administration of ESA three times per week may not best serve patients, and reducing the frequency of dose titrations through use of an ESA dosed once-monthly may result in cost savings due to reduced ESA use.

Objective

• We have developed an economic model to quantify the financial impact of switching from an ESA dosed three times per week, to one dosed monthly, based on reductions in total ESA use.

Methods

• A cost-offset model estimated total ESA utilization and cost for monthly versus 3x/week dosing.

• Utilization inputs for 3x/week dosing were derived from a retrospective study of prevalent (≥ 120 days), adult (≥ 18 years old) hemodialysis patients dialyzing at clinics within a large dialysis organization 3x/week between 1/1/2009 and 12/31/2010 (Table 1).

• A dose titration was defined as a change in ESA dose ≥ 20%. Dose holds (postonements) were not counted as titrations/similarities.

• Only physicians with at least 100 patient-months of data were included in the analysis (N = 2,249).

• Assessments of associations used Pearson product-moment correlation and were adjusted for race, vascular access, mean BMI, mean age, mean vintage and race mix of comorbidities.

• Based on once-monthly ESA data, it was projected that patients on a once-monthly ESA would experience 0.79 titrations per patient-month.

• Price ($0.01/unit, based on epoetin alfa cost derived from published sources), dose and clinical equivalence were assumed across ESAs. Model outcomes included incremental utilization and costs.

Results

• For the 2,249 physicians assessed, the mean number of ESA dose titrations was 0.79 per patient-month (SD = 30.19) and the mean number of Hb measurements was 3.0 per patient-month (median = 2.9, 25th-75th percentile = 2.5-3.6) (Table 2 and Figure 1).

• There was a statistically significant and moderately large correlation between the mean ESA dose titrations per patient-month and ESA use on the physician level. The unadjusted correlation is shown in Figure 2.

Table 1. Demographics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>84,126</td>
</tr>
<tr>
<td>Mean age ± SD (yr)</td>
<td>62.6 ± 14.7</td>
</tr>
<tr>
<td>Mean vintage ± SD (yr)</td>
<td>2.9 ± 1.4</td>
</tr>
<tr>
<td>Female</td>
<td>43.0%</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>3.3%</td>
</tr>
<tr>
<td>Black</td>
<td>36.7%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>16.0%</td>
</tr>
<tr>
<td>Native American</td>
<td>1.3%</td>
</tr>
<tr>
<td>Pacific Islander</td>
<td>0.8%</td>
</tr>
<tr>
<td>White</td>
<td>39.0%</td>
</tr>
<tr>
<td>Other/Unknown</td>
<td>2.8%</td>
</tr>
</tbody>
</table>

• In the adjusted model of the association between titrations/month and ESA use on the physician level, each additional titration per patient per month was associated with an increase of 23,640 units of EPO (95% CI: $20,250, 26,781).

• Under this model, moving from 0.79 titrations/month to 0.29 titrations/month, would generate savings of 11,820 units (95% CI: 10,250, 13,390) of ESA, or $118.20 (95% CI: $102.50, $133.90), per patient-month, assuming price, dose and clinical equivalence.

• More frequent ESA dose titrations are associated with increased ESA use. Each additional monthly dose titration was associated with an increase of $11,347/month.

• The cost-offset model predicted that the decreasing the frequency of ESA dosing from 0.79 titrations/month to 0.29 titrations/month could decrease ESA utilization and reduce costs:

• Projected decreases in utilization and costs from switching to a once-monthly ESA is $1,120/unit/month and $118.20/month, respectively.

• For an average facility with 95 patients, we estimated ESA savings of 1,134,720/unit/month and cost savings of $11,347/month.

• Limitations of the analysis:

• ESA price was based on epoetin alfa costs. The model assumed price, dose and clinical equivalence across ESAs.

• Similar results to those obtained using this model may not be achieved in the real world dialysis setting because target hemoglobin levels and titration guidelines may be different to those in place during the clinical trials from which estimates of the titration frequency using once-monthly ESA were derived.

Figure 1. Physicians’ Average Monthly ESA Dose Titrations per Patient

Figure 2. Scatter Plot of Monthly ESA Dose Titrations vs. ESA Use

Acknowledgements

Our sincere appreciation is extended to the researchers in more than 160 DaVita clinics who work every day to take care of patients but also to ensure the decision-making data they provide is in our best interest. We thank Dr. Brian G. Scott, University of Colorado, for his invaluable contribution in preparing this poster. DCR is committed to advancing the knowledge and practice of kidney care.

References


2. FDA approves Omontys to treat hem in adult patients on dialysis; 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm

